Brokerages Set Liquidia Corporation (NASDAQ:LQDA) PT at $38.56

Shares of Liquidia Corporation (NASDAQ:LQDA) have received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $38.5556.

Several analysts have recently commented on LQDA shares. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Raymond James Financial restated a “strong-buy” rating and issued a $47.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Liquidia in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of Liquidia in a report on Monday, November 3rd.

Insider Buying and Selling at Liquidia

In other news, insider Jason Adair sold 26,057 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $27.86, for a total value of $725,948.02. Following the completion of the transaction, the insider owned 171,029 shares in the company, valued at $4,764,867.94. This trade represents a 13.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 71,381 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total transaction of $1,927,287.00. Following the completion of the sale, the insider owned 176,549 shares of the company’s stock, valued at $4,766,823. This trade represents a 28.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 920,522 shares of company stock worth $25,512,207. Company insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after purchasing an additional 1,173 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Liquidia by 2.9% during the 1st quarter. Bank of New York Mellon Corp now owns 194,131 shares of the company’s stock worth $2,863,000 after buying an additional 5,547 shares during the last quarter. Significant Wealth Partners LLC boosted its position in shares of Liquidia by 14.1% in the 1st quarter. Significant Wealth Partners LLC now owns 14,396 shares of the company’s stock worth $212,000 after buying an additional 1,780 shares in the last quarter. Bleakley Financial Group LLC grew its stake in Liquidia by 6.4% in the 1st quarter. Bleakley Financial Group LLC now owns 25,308 shares of the company’s stock valued at $373,000 after acquiring an additional 1,523 shares during the last quarter. Finally, Cetera Investment Advisers grew its stake in Liquidia by 34.4% in the 1st quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock valued at $619,000 after acquiring an additional 10,756 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Up 1.9%

LQDA opened at $27.78 on Friday. Liquidia has a 52 week low of $9.71 and a 52 week high of $29.94. The business has a 50 day moving average price of $24.47 and a two-hundred day moving average price of $20.07. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The company has a market cap of $2.42 billion, a PE ratio of -19.29 and a beta of 0.12.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. As a group, research analysts anticipate that Liquidia will post -1.51 EPS for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).